Peptide CDMO Market Size, Share, Growth, and Industry Analysis, By Type (LPPS,SPPS,Mixed Phase), By Application (Pharmaceutical Industry,Cosmetics Industry,Others), Regional Insights and Forecast to 2035

Peptide CDMO Market Overview

The global Peptide CDMO Market is forecast to expand from USD 5698.14 million in 2026 to USD 6845.18 million in 2027, and is expected to reach USD 29691.11 million by 2035, growing at a CAGR of 20.13% over the forecast period.

The Peptide CDMO Market has shown significant momentum due to increased outsourcing in pharmaceutical manufacturing. In 2024, more than 65% of peptide production globally was outsourced to specialized CDMOs, highlighting the strong reliance of pharma companies on external partners. Around 42% of small-to-mid-size biotech firms engaged in peptide development rely exclusively on CDMOs for synthesis, scale-up, and regulatory compliance support. In terms of production, solid-phase peptide synthesis accounted for nearly 58% of commercial-scale production, while liquid-phase methods captured 27%, and mixed-phase accounted for 15% of output.

The United States dominates the global Peptide CDMO Market with approximately 33% market share in 2024, driven by the country’s strong biopharmaceutical innovation base. More than 55% of peptide-based clinical trials worldwide are sponsored by U.S.-based biotech and pharma companies. In terms of outsourcing, nearly 68% of American mid-sized pharmaceutical companies depend on CDMOs for large-scale peptide synthesis, process optimization, and regulatory filings.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 62% of pharmaceutical firms outsourced peptide manufacturing in 2024, driven by increasing demand for accelerated drug development and stringent global regulatory compliance.
• Major Market Restraint: Around 41% of CDMOs reported rising costs and scalability issues, significantly affecting smaller biotech firms investing in advanced peptide drug development projects worldwide.
• Emerging Trends: Nearly 54% of CDMOs adopted AI-driven automation, and 29% integrated advanced purification technologies, improving production efficiency, yield, and reducing peptide synthesis errors.
• Regional Leadership: North America dominated with 37% share, followed by Europe at 30%, and Asia-Pacific’s rising influence, reaching 26% of the global peptide outsourcing market.
• Competitive Landscape: The top five CDMOs controlled 46% share, with Bachem holding 24% and PolyPeptide 22%, leading peptide outsourcing through strong global production capacity.
• Market Segmentation: Solid-phase synthesis represented 58%, liquid-phase 27%, and mixed-phase 15% share. Applications included pharmaceuticals at 70%, cosmetics 20%, and diagnostics or others at 10%.
• Recent Development: Around 32% of CDMOs expanded facilities between 2023–2024, while 18% launched automated synthesis platforms, improving peptide purity, scalability, and production turnaround times.

Peptide CDMO Market Latest Trends

The Peptide CDMO Market has witnessed new trends with over 60% of companies integrating AI and digitalization into peptide design and production workflows. Between 2023 and 2024, about 36% of peptide outsourcing projects shifted toward oncology-related therapies, highlighting a growing therapeutic focus.

Additionally, nearly 22% of CDMOs expanded their operations into peptide-based cosmetic formulations, fueled by increasing consumer demand for anti-aging products. Sustainability has become a trend, with 28% of CDMOs adopting green chemistry protocols and waste reduction systems. Flexible manufacturing contracts grew by 19% from 2022 to 2024, allowing smaller firms to access premium synthesis platforms without heavy upfront investments.

Peptide CDMO Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

In 2024, the pharmaceutical industry accounted for nearly 70% of peptide CDMO demand, with 58% linked to peptide-based drug formulations. More than 64% of biotech firms with peptide-focused portfolios engaged in CDMO partnerships for cost reduction and access to advanced synthesis technologies. The rise of peptide-based cancer therapies, representing 38% of ongoing peptide trials, further fueled outsourcing growth. Additionally, about 29% of CDMOs reported increased long-term contracts with major pharmaceutical companies, reflecting the strategic reliance of global pharma on specialized peptide manufacturers.

RESTRAINT

"Demand for refurbished equipment."

High production and operational costs constrained the Peptide CDMO Market, with nearly 41% of companies citing cost escalation as a major restraint. Around 35% of small biotech firms delayed peptide drug development projects due to cost overruns in outsourcing. Furthermore, nearly 25% of CDMOs reported limited scalability issues when moving from lab-scale synthesis to full commercial-scale production. Strict quality standards also led to 18% of rejected batches in 2024, resulting in increased expenditure and reduced efficiency. The high cost of purified peptide manufacturing remains a restraint for market expansion.

OPPORTUNITY

"Growth in personalized medicines."

Personalized medicine adoption is a major opportunity, with 42% of peptide CDMOs expanding capabilities in custom synthesis. In 2024, nearly 33% of outsourcing projects focused on personalized oncology treatments. Around 27% of CDMOs collaborated with precision medicine companies, while 21% invested in modular facilities to accelerate tailored peptide production. Furthermore, 38% of peptide-related patent filings in 2023–2024 were linked to personalized medicine technologies, opening new avenues for customized peptide therapies. This trend strongly supports market expansion by increasing demand for specialized manufacturing partnerships.

CHALLENGE

"Rising costs and expenditures."

Rising raw material prices created a challenge for the Peptide CDMO Market, with 39% of companies reporting procurement difficulties for specialized amino acids. Nearly 28% of firms faced additional costs due to stringent regulatory compliance and quality certifications. Around 30% of CDMOs cited talent shortages for specialized peptide synthesis, causing delays in development projects. Additionally, 21% of outsourcing firms highlighted risks of batch variability, impacting consistency in peptide delivery. Rising energy costs in production facilities also contributed to a 17% cost increase for large-scale peptide manufacturing operations globally.

Peptide CDMO Market Segmentation

The Peptide CDMO Market is segmented by type into LPPS, SPPS, and Mixed Phase, and by application into pharmaceutical, cosmetics, and other industrial uses. Each segment contributed measurable shares, highlighting distinct growth patterns and end-user adoption in 2024.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

LPPS: Liquid-phase peptide synthesis accounted for 27% of global peptide production, primarily applied in large-scale industrial manufacturing. Nearly 61% of bulk peptide exports from Asia-Pacific utilized LPPS methods due to high scalability and cost-effectiveness. This method is increasingly chosen by cosmetics companies for shorter peptide chain applications.

The LPPS segment in the global Peptide CDMO Market is projected to reach USD 1124.56 million by 2025, holding 23.7% share, with a CAGR of 18.92% through 2034.

Top 5 Major Dominant Countries in the LPPS Segment

• The United States LPPS market is expected to reach USD 298.77 million by 2025, holding 26.5% share, growing steadily with a CAGR of 19.11% through 2034.
• Germany LPPS market size will touch USD 164.34 million in 2025, capturing 14.6% share, supported by a strong pharmaceutical base and CAGR growth of 18.45%.
• China LPPS market size will be USD 192.25 million in 2025, accounting for 17.1% share, expanding significantly with an impressive CAGR of 20.02% through 2034.
• Japan LPPS market size is estimated at USD 129.51 million in 2025, securing 11.5% share, with strong peptide innovation pipelines and a CAGR of 17.68%.
• France LPPS market size will reach USD 112.44 million in 2025, achieving 10% share, with biopharma outsourcing growth and a CAGR of 18.04% through 2034.

SPPS: Solid-phase peptide synthesis dominated with 58% share in 2024, particularly in pharmaceuticals. About 72% of peptide APIs for clinical drug development were manufactured using SPPS. More than 45% of oncology-related peptides used this method due to its efficiency in synthesizing complex and long-chain peptides for advanced therapeutics.

The SPPS segment dominates the global Peptide CDMO Market, valued at USD 2816.13 million in 2025, capturing 59.3% share, advancing robustly with a CAGR of 20.44% through 2034.

Top 5 Major Dominant Countries in the SPPS Segment

• The United States SPPS market size is expected to hit USD 784.12 million in 2025, controlling 27.8% share, maintaining leadership with a CAGR of 20.91% through 2034.
• Switzerland SPPS market will be USD 436.44 million in 2025, with 15.5% share, driven by advanced CDMOs, growing strongly with a CAGR of 19.76%.
• China SPPS market is projected at USD 505.23 million in 2025, representing 17.9% share, expanding rapidly with a CAGR of 21.32% during 2025–2034.
• India SPPS market will reach USD 314.89 million in 2025, securing 11.2% share, rising with affordable outsourcing strengths and a CAGR of 20.11%.
• Germany SPPS market size is USD 281.64 million in 2025, capturing 10% share, supported by industrial demand with a CAGR of 19.42% through 2034.

Mixed Phase: Mixed-phase synthesis represented 15% share, combining benefits of both LPPS and SPPS. Nearly 23% of newly developed peptides in 2023–2024 used mixed-phase approaches. Around 19% of CDMOs adopted this technique for high-purity peptides, primarily for diagnostic and research purposes.

The Mixed Phase segment of the Peptide CDMO Market is forecasted at USD 802.62 million in 2025, representing 17% share, advancing significantly with a CAGR of 19.89% through 2034.

Top 5 Major Dominant Countries in the Mixed Phase Segment

• The United States Mixed Phase market is estimated at USD 224.73 million in 2025, commanding 28% share, with broad clinical adoption and a CAGR of 20.14%.
• China Mixed Phase market size will reach USD 160.52 million in 2025, 20% share, expanding with biopharma growth and a CAGR of 20.76% through 2034.
• Japan Mixed Phase market size is USD 120.39 million in 2025, holding 15% share, benefiting from therapeutic peptide growth with a CAGR of 18.98%.
• Germany Mixed Phase market size is USD 104.34 million in 2025, 13% share, supported by strong R&D infrastructure, growing at a CAGR of 19.21%.
• South Korea Mixed Phase market is USD 72.23 million in 2025, 9% share, rising with peptide cosmetics innovation, advancing with CAGR 19.65% through 2034.

BY APPLICATION

Pharmaceutical Industry: With 70% of applications, pharmaceuticals dominated peptide demand. More than 68% of ongoing peptide-related clinical trials focused on therapeutic applications. Around 40% of new peptide drugs targeted oncology, followed by 28% for metabolic disorders and 18% for infectious diseases.

The pharmaceutical application dominates, valued at USD 3320.32 million in 2025, holding 70% share, advancing strongly with a CAGR of 20.54% due to rising peptide-based drug development globally.

Top 5 Major Dominant Countries in the Pharmaceutical Application

• The United States pharmaceutical peptide market will reach USD 929.69 million in 2025, 28% share, advancing with a CAGR of 20.98% due to oncology drug outsourcing.
• China pharmaceutical peptide market is USD 664.06 million in 2025, 20% share, rapidly growing with a CAGR of 21.33% supported by strong peptide clinical pipelines.
• Switzerland pharmaceutical peptide market size is USD 464.84 million in 2025, 14% share, advancing with leading CDMOs and a CAGR of 19.84% through 2034.
• India pharmaceutical peptide market will be USD 398.44 million in 2025, 12% share, growing with competitive outsourcing and a CAGR of 20.12%.
• Germany pharmaceutical peptide market stands at USD 332.03 million in 2025, 10% share, expanding with biopharma investments and a CAGR of 19.61%.

Cosmetics Industry: The cosmetics industry held 20% share in 2024, with anti-aging peptides accounting for 34% of formulations. Nearly 25% of new skincare launches included peptide-based ingredients, with Europe representing 41% of cosmetic peptide consumption globally.

The cosmetics application accounts for USD 711.50 million in 2025, 15% share, with a CAGR of 19.47%, boosted by anti-aging and dermatology peptide-based formulations globally.

Top 5 Major Dominant Countries in the Cosmetics Application

• France cosmetics peptide market is USD 142.30 million in 2025, 20% share, growing with beauty sector expansion, supported by CAGR of 19.72%.
• South Korea cosmetics peptide market will be USD 128.07 million in 2025, 18% share, expanding with K-beauty dominance and a CAGR of 19.91%.
• Japan cosmetics peptide market size is USD 106.72 million in 2025, 15% share, rising with skincare peptide adoption, CAGR of 18.89%.
• United States cosmetics peptide market will be USD 99.61 million in 2025, 14% share, expanding with luxury skincare brands and a CAGR of 19.26%.
• Germany cosmetics peptide market size is USD 85.38 million in 2025, 12% share, expanding with premium cosmetic products, CAGR of 18.97%.

Others: Other applications represented 10%, including diagnostics, veterinary, and food technology uses. Around 14% of diagnostic assay kits launched in 2023–2024 contained peptide biomarkers, while 8% of veterinary peptide-based vaccines used outsourced CDMO services.

Other applications, including diagnostics, veterinary, and food sectors, are valued at USD 711.49 million in 2025, holding 15% share, advancing steadily with CAGR of 19.88% worldwide.

Top 5 Major Dominant Countries in Other Applications

• United States others market will be USD 170.76 million in 2025, 24% share, rising with diagnostics growth, advancing CAGR of 20.02%.
• China others peptide market is USD 142.30 million in 2025, 20% share, advancing with biotech expansion, CAGR 20.34%.
• Germany others peptide market size is USD 106.72 million in 2025, 15% share, driven by healthcare applications, CAGR 19.21%.
• India others peptide market will be USD 92.49 million in 2025, 13% share, growing steadily with diagnostics and veterinary, CAGR 19.67%.
• Japan others peptide market size is USD 78.26 million in 2025, 11% share, advancing with clinical diagnostics, CAGR 18.89%.

Peptide CDMO Market Regional Outlook

Regionally, the Peptide CDMO Market showed diverse adoption across North America, Europe, Asia-Pacific, and the Middle East & Africa. Market performance highlighted distinct regional leadership and increasing demand for outsourcing services globally.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounted for 37% share in 2024, with the U.S. dominating peptide outsourcing activities. More than 55% of peptide-based clinical trials occurred in the U.S., while Canada contributed 9% of regional peptide production. Around 63% of leading global peptide CDMOs maintained facilities across North America.

North America Peptide CDMO Market is valued at USD 1754.03 million in 2025, securing 37% share, expanding at a CAGR of 20.41%.

North America – Major Dominant Countries in the Peptide CDMO Market

• The United States Peptide CDMO market leads with USD 1391.25 million in 2025, commanding 79% regional share, expanding rapidly at a CAGR of 20.92%.
• Canada market size reaches USD 210.48 million in 2025, representing 12% regional share, steadily advancing through pharmaceutical outsourcing with a CAGR of 19.88%.
• Mexico market accounts for USD 87.70 million in 2025, capturing 5% regional share, supported by growing CDMO investments, recording a CAGR of 19.22%.
• Cuba market stands at USD 35.08 million in 2025, holding 2% share, rising gradually with healthcare expansion, advancing at a CAGR of 18.56%.
• Caribbean region collectively generates USD 29.52 million in 2025, maintaining 2% share, supported by niche biotechnology growth, recording a CAGR of 18.11%.

EUROPE

Europe represented 30% share, with Germany, Switzerland, and the U.K. leading peptide outsourcing demand. About 44% of European peptides were linked to cosmetic formulations. Switzerland accounted for 19% of regional peptide manufacturing due to its concentration of CDMO facilities and advanced biopharma infrastructure.

Europe Peptide CDMO Market is estimated at USD 1422.99 million in 2025, securing 30% share, advancing strongly with a CAGR of 19.98% through 2034.

Europe – Major Dominant Countries in the Peptide CDMO Market

• Switzerland dominates the European market with USD 426.89 million in 2025, controlling 30% regional share, advancing at a CAGR of 19.87%.
• Germany market size stands at USD 355.75 million in 2025, capturing 25% share, supported by strong biotech outsourcing demand, with a CAGR of 19.66%.
• France contributes USD 284.60 million in 2025, representing 20% regional share, expanding with cosmetic peptide adoption, advancing at a CAGR of 19.44%.
• United Kingdom market achieves USD 213.44 million in 2025, holding 15% share, growing with pharmaceutical outsourcing trends, recording a CAGR of 18.92%.
• Italy generates USD 142.29 million in 2025, securing 10% share, expanding with biotech investments and outsourcing, with a CAGR of 18.61%.

ASIA-PACIFIC

Asia-Pacific grew to 26% share, driven by China, India, and Japan. Nearly 47% of peptide exports worldwide originated from Asia-Pacific, with China alone contributing 28%. India accounted for 15% of global peptide generic manufacturing, showcasing the region’s expanding cost-effective outsourcing base.

Asia-Pacific Peptide CDMO Market is projected at USD 1233.26 million in 2025, representing 26% share, advancing robustly with a CAGR of 21.05% during the forecast period.

Asia-Pacific – Major Dominant Countries in the Peptide CDMO Market

• China market leads Asia-Pacific with USD 431.64 million in 2025, accounting for 35% share, expanding rapidly with a CAGR of 21.33%.
• India captures USD 308.31 million in 2025, representing 25% share, driven by affordable outsourcing advantages, advancing at a CAGR of 20.87%.
• Japan generates USD 246.65 million in 2025, securing 20% share, supported by therapeutic peptide growth, recording a CAGR of 20.02%.
• South Korea contributes USD 123.33 million in 2025, holding 10% share, expanding with peptide cosmetics development, achieving a CAGR of 19.44%.
• Australia market stands at USD 123.33 million in 2025, also 10% share, benefiting from clinical outsourcing projects, advancing with CAGR 19.26%.

MIDDLE EAST & AFRICA

The Middle East & Africa collectively contributed 7% share, with South Africa leading at 3%. The UAE invested in peptide research hubs, accounting for 2% of regional peptide projects. Around 18% of regional outsourcing contracts were linked to diagnostic and cosmetic applications.

Middle East and Africa Peptide CDMO Market is forecasted at USD 332.03 million in 2025, holding 7% share, expanding with CAGR of 18.94% through 2034.

Middle East and Africa – Major Dominant Countries in the Peptide CDMO Market

• South Africa dominates the region with USD 99.61 million in 2025, representing 30% share, expanding steadily at a CAGR of 19.02%.
• UAE market size stands at USD 66.41 million in 2025, securing 20% share, benefiting from biotech investments, recording a CAGR of 18.77%.
• Saudi Arabia generates USD 59.76 million in 2025, holding 18% share, advancing with peptide-based research growth, achieving a CAGR of 18.56%.
• Egypt accounts for USD 46.48 million in 2025, representing 14% share, expanding with diagnostic peptide demand, recording a CAGR of 18.21%.
• Nigeria market reaches USD 39.84 million in 2025, capturing 12% share, supported by healthcare biotechnology, growing with a CAGR of 17.96%.

List of Top Peptide CDMO Companies

• PolyPeptide
• Provepharm
• Piramal Pharma
• Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd
• ScinoPharm
• Space Peptides
• AmbioPharm
• Thermo Fisher Pharma
• CordenPharma
• Chengdu Shengnuo Biotechnology Co., Ltd
• Bachem
• Alabiochem
• Alpha Biophama
• CBL
• Aurigene Pharmaceutical Services
• CPC Scientific
• Biopeptek

Top Companies:

• Bachem held nearly 24% of global share in 2024, supported by advanced GMP-certified facilities.
• PolyPeptide followed with 22%, offering large-scale outsourcing contracts across pharmaceuticals and cosmetic peptides worldwide.

Investment Analysis and Opportunities

Investments in the Peptide CDMO Market expanded rapidly between 2023 and 2025, with 36% of CDMOs increasing capacity through new facility construction and modernization. Nearly 21% of firms secured private equity funding to enhance automation in peptide synthesis. Around 29% of biotech start-ups partnered with CDMOs for co-investment models, reducing R&D risks while accelerating timelines.

Cross-border investments grew by 18%, particularly between Europe and Asia-Pacific, enabling knowledge exchange and capacity scaling. Furthermore, 32% of CDMOs invested in environmentally sustainable processes to attract eco-conscious clients. The rise of biologics and peptide-based personalized medicine created opportunities, with more than 41% of new investments directed toward modular manufacturing.

New Product Development

New product development in the Peptide CDMO Market accelerated with 34% of CDMOs launching advanced synthesis technologies between 2023 and 2025. About 22% of companies introduced long peptide APIs for oncology pipelines, reflecting increased therapeutic focus. Peptide-based cosmetic formulations represented 18% of new developments in 2024, primarily anti-aging and skin-repair peptides.

Around 27% of CDMOs developed hybrid synthesis platforms that integrated LPPS and SPPS for efficiency and purity. Innovative purification technologies, including preparative HPLC, were adopted by 39% of CDMOs to meet high purity standards. Furthermore, 24% of newly launched peptides targeted metabolic diseases, while 19% were for cardiovascular disorders.

Five Recent Developments

• Bachem expanded a Swiss peptide manufacturing facility by 15% capacity in 2024, targeting oncology APIs and complex long peptides for clinical applications.
• PolyPeptide introduced an AI-enabled peptide synthesis platform in 2023, boosting productivity by 21% across its European facilities.
• AmbioPharm announced the launch of new peptide vaccine APIs in 2024, contributing 12% to its annual peptide portfolio.
• Thermo Fisher Pharma added a 25% capacity expansion in U.S.-based peptide CDMO services in 2025, enhancing oncology peptide pipelines.
• CordenPharma collaborated with a biotech start-up in 2025 to co-develop peptide-based metabolic drugs, covering 18% of its R&D activities.

Report Coverage of Peptide CDMO Market

The Peptide CDMO Market Report provides comprehensive coverage of outsourcing dynamics, highlighting production by type, application, and regional performance. With over 600 peptide candidates under development globally, the report covers industry analysis, market share, and demand patterns. It analyzes pharmaceutical dominance, which accounted for 70% of applications in 2024, alongside cosmetics at 20% and others at 10%.

The report outlines North America’s 37% leadership, Europe’s 30%, and Asia-Pacific’s growing 26% presence. The competitive landscape emphasizes the top 15+ CDMOs, with Bachem and PolyPeptide collectively holding 46% share. Investment analysis identifies trends such as 32% facility expansions, 21% adoption of AI-driven platforms, and 18% sustainability-focused upgrades.

Peptide CDMO Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5698.14 Million in 2026
Market Size Value By	USD 29691.11 Million by 2035
Growth Rate	CAGR of 20.13% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : LPPS SPPS Mixed Phase By Application : Pharmaceutical Industry Cosmetics Industry Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample